Sermorelin
Swipe right to view full table →
Save over 70%!
Product Format |
10mg vials |
Vial Size |
10mg |
Vial Capacity |
3 mL |
Box Combinations |
20mg, 50mg, 100mg, 200mg |
Cost per milligram |
$3.98 – $4.90 |
Multi-vial Purity |
99.94% |
Endotoxin Screening |
PASSED |
Heavy Metals Screening |
PASSED |
Purity Screening |
PASSED |
Independently Tested |
YES |
- Peptide Partners Manufacturer ID: VI32
- Batch ID: SER202601
Research Studies
(for research purposes only)
Study 1: A potentially effective drug for patients with recurrent glioma: sermorelin
Authors: Chang Y, Huang R, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W, Hu H.
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC8033379/
Scientific Findings
The study investigated the effect of sermorelin on glioma cell lines U87 and LN229. The results showed that sermorelin inhibited the proliferation of these cells in a dose-dependent manner. The study suggests that sermorelin may inhibit tumor cell proliferation by blocking the cell cycle. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analyses found that the Drug Resistance Score (DRS) of sermorelin was negatively correlated with cell proliferation and immune function.
Plain English Interpretation
This research explored whether the peptide Sermorelin could be a potential treatment for a type of brain tumor called glioma. The scientists tested Sermorelin on cancer cells in a lab dish and found that it could stop the cancer cells from growing. The study suggests that Sermorelin might work by interfering with the cancer cells’ ability to divide and multiply. It also seems to boost the immune system’s ability to fight the cancer. This is an early-stage study, but it suggests that Sermorelin could be a promising new drug for patients with recurrent glioma.
Study 2: Advances in the detection of growth hormone releasing hormone synthetic analogs
Authors: Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V.
Source: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3183
Scientific Findings
This study investigates the in vitro metabolism of four growth hormone-releasing hormone (GHRH) synthetic analogs, including sermorelin, in fortified urine for anti-doping purposes. The researchers identified nineteen major in vitro metabolites of these GHRH analogs. For sermorelin, several degradation products were identified, which will aid in the development of more effective detection methods for its misuse in sports.
Plain English Interpretation
Scientists in this study were looking for a way to detect if athletes are illegally using substances like Sermorelin to enhance their performance. They developed a method to find these substances in urine. In the lab, they mixed Sermorelin with urine and observed how it breaks down. They identified several smaller pieces, or ‘metabolites’. Knowing what these metabolites look like is crucial for creating a reliable drug test, because the test can then look for these specific markers.
Study 3: Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS
Authors: Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M.
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC4830873/
Scientific Findings
This study aimed to develop a method for detecting various growth hormone-releasing hormones (GHRHs), including Sermorelin, in human plasma for anti-doping purposes. In an in-vitro experiment, Sermorelin was incubated in human plasma. The researchers observed that Sermorelin was completely degraded after 4 hours. They identified a metabolite, GRF(3-29), which results from the cleavage of the N-terminal Tyr-Ala-residue by the enzyme dipeptidyl peptidase-IV (DPP-IV). This finding is important for developing effective anti-doping tests, as it’s often the metabolites of a substance, rather than the substance itself, that are detected in biological samples.
Plain English Interpretation
Scientists in this study were looking for a way to detect if athletes are illegally using substances like Sermorelin to enhance their performance. They developed a method to find these substances in blood. In the lab, they mixed Sermorelin with human blood plasma and observed how it breaks down. They found that Sermorelin is broken down into a smaller piece, a ‘metabolite’. Knowing what this metabolite looks like is crucial for creating a reliable drug test, because the test can then look for this specific marker.
Storage:
All of our manufacturing partners produce peptides using the Lyophilization (Freeze Drying) process, ensuring products maintain stability for shipping and storage for 12+ months.
In lyophilized form, they are shelf-stable for many weeks. However, for long-term storage, it is recommended to store them in the freezer.
We often hear concerns about the standard “discard after 28 days of first use” disclaimer. Don’t worry, this has nothing to do with studies regarding the efficacy of specific peptides. 28 days is the FDA requirement for producers of multi-use vials to prove their bacteriostatic maintains efficacy. This minimum requirement becomes the de facto standard.
In our experience, if you use proper sterile procedures and refrigerated storage, you can continue sampling from the same reconstituted vial for 3+ months.
Third-party testing
Peptide Partners is committed to providing high-purity peptides at wholesale prices by frequently auditing its manufacturing partners using third-party laboratories. Independent analysis is vital to ensuring the quality and authenticity of your research peptides. Never trust a supplier that doesn’t submit to third-party testing. Never trust a certification that cannot be independently verified. All of the certificates that we provide can be validated on the third-party laboratory’s website.
Each product description contains a Manufacturer ID corresponding to the producer of that product. The table below contains the most recent third-party analyses for all manufacturers and peptides listed on Peptide Partners.
Current Purity certifications
|
Peptide |
Batch Id |
Manufacturer |
Date |
Purity |
Laboratory |
Double Validated |
|
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-07-02 |
99.71% |
Kovera |
||
|
Reconstitution Solution |
BAC202606 |
WF03 |
2026-07-13 |
99.9% |
Kovera |
||
|
Retatrutide |
RTT2613 |
WF03 |
2026-07-02 |
99.77% |
Kovera |
||
|
PT-141 |
PT202605 |
VI32 |
2026-06-25 |
99.74% |
Kovera |
||
|
Tesamorelin |
TES202607 |
WF03 |
2026-06-19 |
99.80% |
TrustPointe |
||
|
KPV |
KV202606 |
WF03 |
2026-06-12 |
99.36% |
TrustPointe |
Yes |
|
|
BPC-157 |
BC202607 |
WF03 |
2026-06-12 |
99.82% |
TrustPointe |
Yes |
|
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-12 |
99.98% |
TrustPointe |
Yes |
|
|
Semaglutide |
SM202607 |
VI32 |
2026-06-12 |
99.96% |
TrustPointe |
Yes |
|
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
99.36% |
Kovera |
Yes |
|
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-10 |
99.88% |
TrustPointe |
Yes |
|
|
BPC-157 |
BC202607 |
WF03 |
2026-06-10 |
99.74% |
Kovera |
Yes |
|
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-10 |
99.71% |
Kovera |
Yes |
|
|
Retatrutide |
RT202607 |
WF03 |
2026-06-09 |
99.76% |
Kovera |
||
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-09 |
99.55% |
Kovera |
Yes |
|
|
Semaglutide |
SM202607 |
VI32 |
2026-06-10 |
99.68% |
Kovera |
Yes |
|
|
KPV |
KV202606 |
WF03 |
2026-06-10 |
99.70% |
Kovera |
Yes |
|
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-10 |
99.34% |
TrustPointe |
Yes |
|
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-09 |
99.65% |
Kovera |
Yes |
|
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-09 |
99.90% |
Kovera |
Yes |
|
|
NAD+ |
NDB202606 |
WF03 |
2026-05-28 |
99.55% |
TrustPointe |
||
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-13 |
99.67% |
TrustPointe |
||
|
Epithalon |
ET202604 |
WF03 |
2026-05-13 |
99.86% |
Kovera |
||
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-13 |
99.78% |
Kovera |
Yes |
|
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-29 |
99.53% |
Chromate |
Yes |
|
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-11 |
99.22% |
TrustPointe |
Yes |
|
|
MOTS-c |
MC202605 |
WF03 |
2026-06-08 |
99.98% |
TrustPointe |
||
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-08 |
99.94% |
TrustPointe |
Yes |
|
|
TB-500 (TB4) |
TB202605 |
WF03 |
2026-05-28 |
99.76% |
TrustPointe |
||
|
Tesamorelin |
TES202605 |
WF03 |
2026-05-28 |
99.81% |
TrustPointe |
||
|
Retatrutide |
RT202605 |
WF03 |
2026-05-27 |
99.75% |
TrustPointe |
||
|
Reconstitution Solution |
BAC202602 |
VI32 |
2026-05-14 |
99.90% |
Kovera |
||
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-14 |
99.93% |
TrustPointe |
||
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-14 |
99.74% |
TrustPointe |
||
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-05-14 |
99.73% |
TrustPointe |
Yes |
|
|
GHK-Cu |
CU202604 |
WF03 |
2026-05-14 |
99.74% |
TrustPointe |
Yes |
|
|
BPC-157 |
BC202604 |
VI32 |
2026-05-13 |
99.72% |
TrustPointe |
Yes |
|
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-05-07 |
99.82% |
Kovera |
||
|
Tesamorelin |
TES202604 |
WF03 |
2026-04-21 |
99.85% |
Kovera |
||
|
DSIP |
DS202605 |
WF03 |
2026-05-07 |
99.81% |
Kovera |
||
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
99.90% |
Kovera |
Yes |
|
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
99.86% |
Kovera |
||
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
99.93% |
Kovera |
||
|
Cagrilintide |
CG202603 |
VI32 |
2026-04-14 |
99.90% |
Kovera |
||
|
MOTS-c |
MC202603 |
VI32 |
2026-04-04 |
99.96% |
Kovera |
||
|
Retatrutide |
RT202604 |
WF03 |
2026-04-16 |
99.54% |
TrustPointe |
||
|
Sermorelin |
SER202601 |
VI32 |
2026-04-01 |
99.94% |
Kovera |
||
|
Pinealon |
PN202603 |
WF03 |
2026-04-01 |
99.96% |
Kovera |
||
|
GHK-Cu |
CU202604 |
WF03 |
2026-04-03 |
99.93% |
Kovera |
Yes |
|
|
SS-31 |
SS202601 |
WF03 |
2026-04-03 |
99.82% |
TrustPointe |
||
|
Semax |
SX202603 |
WF03 |
2026-03-31 |
99.91% |
Kovera |
||
|
Retatrutide |
RT202603 |
WF03 |
2026-03-30 |
99.40% |
TrustPointe |
||
|
GLOW Blend |
GW202603 |
WF03 |
2026-03-25 |
99.88% |
Kovera |
||
|
Tirzepatide |
TZ202603 |
VI32 |
2026-03-27 |
99.89% |
TrustPointe |
||
|
BPC-157/TB-500 |
BB202604 |
WF03 |
2026-03-27 |
99.63% |
TrustPointe |
||
|
Tesamorelin |
TES202603 |
WF03 |
2026-03-25 |
99.52% |
TrustPointe |
||
|
BPC-157 |
BC202604 |
VI32 |
2026-03-18 |
99.60% |
TrustPointe |
Yes |
|
|
Ipamorelin/CJC-1295 (No DAC) |
CJIP202602 |
WF03 |
2026-02-27 |
99.92% |
TrustPointe |
||
|
Thymosin Alpha-1 |
TA202602 |
WF03 |
2026-02-25 |
99.95% |
Kovera |
||
|
KLOW |
KW202602 |
WF03 |
2026-03-01 |
99.86% |
Chromate |
||
|
NAD+ |
NDB202601 |
VI32 |
2026-02-07 |
99.92% |
Kovera |
||
|
SS-31 |
SS202602 |
WF03 |
2026-02-08 |
99.68% |
Chromate |
||
|
MOTS-c |
MC202602 |
WF03 |
2026-02-09 |
99.41% |
Chromate |
||
|
Selank |
SEK202601 |
VI32 |
2026-01-29 |
99.94% |
Chromate |
||
|
Unbuffered NAD+ |
NDU202601 |
MZ21 |
2026-01-20 |
99.85% |
Chromate |
||
|
KPV |
KV202601 |
VI32 |
2026-01-20 |
99.90% |
Chromate |
||
|
Ipamorelin |
IP202601 |
WF03 |
2026-01-14 |
99.92% |
TrustPointe |
||
|
TB500 (TB4) |
TB202601 |
WF03 |
2026-01-14 |
99.86% |
TrustPointe |
||
|
Retatrutide |
RT202602 |
WF03 |
2026-01-13 |
99.63% |
TrustPointe |
||
|
PT-141 |
PT202512 |
VI32 |
2026-01-12 |
99.89% |
BioRegen |
||
|
Semaglutide |
SM202601 |
MZ21 |
2026-01-10 |
99.70% |
TrustPointe |
||
|
Cagrilintide |
CAG202601 |
MZ21 |
2026-01-10 |
99.33% |
TrustPointe |
||
|
Tesamorelin |
TES202601 |
WF03 |
2025-12-29 |
99.71% |
TrustPointe |
||
|
BPC-157 |
BP202512 |
WF03 |
2025-12-29 |
99.46% |
TrustPointe |
||
|
BPC-157/TB-500 |
BB202512 |
WF03 |
2025-12-29 |
99.64% |
TrustPointe |
||
|
GHK-Cu |
GK202512 |
SH07 |
2025-12-19 |
99.79% |
BioRegen |
||
|
MOTS-c |
MC202512 |
WF03 |
2025-12-22 |
99.89% |
BioRegen |
||
|
Retatrutide |
RP260130 |
VI32 |
2025-12-22 |
99.72% |
TrustPointe |
||
|
SS-31 |
SS202512 |
WF03 |
2025-12-19 |
99.70% |
TrustPointe |
||
|
Retatrutide |
RP202601 |
DF05 |
2025-12-22 |
99.63% |
TrustPointe |
||
|
Ipamorelin/CJC-1295 (No DAC) |
CJIP202512 |
WF03 |
2025-12-09 |
99.80% |
TrustPointe |
||
|
Retatrutide |
RP202511 |
DF05 |
2025-12-19 |
99.73% |
TrustPointe |
||
|
Retatrutide |
RP20251020 |
DF05 |
2025-11-10 |
99.33% |
TrustPointe |
||
|
Retatrutide |
RP20251001 |
DF05 |
2025-10-13 |
99.86% |
TrustPointe |
||
|
Tirzepatide |
TZ20250915 |
DF05 |
2025-10-03 |
99.74% |
TrustPointe |
||
|
Retatrutide |
RP20250929 |
VI32 |
2025-10-03 |
99.47% |
TrustPointe |
||
|
Humanin |
HP20250805 |
WF03 |
2025-09-19 |
99.92% |
BioRegen |
||
|
MOTS-c |
YC20250807 |
WF03 |
2025-09-19 |
99.87% |
BioRegen |
||
|
DSIP |
DS20250820 |
SH07 |
2025-09-19 |
99.88% |
BioRegen |
||
|
SS-31 |
SY20250806 |
WF03 |
2025-09-19 |
99.70% |
BioRegen |
||
|
CJC/Ipamorelin |
CI20250805 |
WF03 |
2025-09-11 |
99.84% |
TrustPointe |
||
|
BPC-157 |
BP20250808 |
WF03 |
2025-09-05 |
99.99% |
TrustPointe |
||
|
Sermorelin |
SM20250723 |
WF03 |
2025-08-27 |
99.84% |
BioRegen |
||
|
Tesamorelin |
TS20250722 |
WF03 |
2025-08-22 |
99.10% |
TrustPointe |
||
|
CJC-1295 ND |
CJ20250724 |
WF03 |
2025-08-20 |
99.43% |
TrustPointe |
||
|
Semaglutide |
SM20250801 |
EJ12 |
2025-08-20 |
99.34% |
TrustPointe |
||
|
Ipamorelin |
IP20250721 |
WF03 |
2025-08-15 |
99.64% |
TrustPointe |
||
|
GHK-Cu |
CU20250717 |
SH07 |
2025-08-09 |
99.73% |
BioRegen |
||
|
Tirzepatide |
TZ20250730 |
EJ12 |
2025-08-08 |
99.41% |
TrustPointe |
||
|
NAD+ |
ND20250503 |
SH07 |
2025-07-31 |
99.76% |
BioRegen |
||
|
VIP |
VP20250511 |
SH07 |
2025-07-31 |
99.42% |
BioRegen |
||
|
Retatrutide |
CD20250708 |
SH07 |
2025-07-25 |
99.42% |
TrustPointe |
||
|
BPC/TB500 |
BB20250630 |
SH07 |
2025-07-17 |
99.52% |
TrustPointe |
||
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-07-17 |
99.68% |
TrustPointe |
Current Endotoxin Certifications
|
Peptide |
Batch Id |
Manufacturer |
Date |
USP Conformation |
Laboratory |
|
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-06-30 |
Conforms |
Kovera |
|
|
Reconstitution Solution |
BAC202606 |
WF03 |
2026-07-13 |
Conforms |
Kovera |
|
|
Retatrutide |
RTT2613 |
WF03 |
2026-06-30 |
Conforms |
Kovera |
|
|
Tesamorelin |
TES202607 |
WF03 |
2026-06-22 |
Conforms |
TrustPointe |
|
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-15 |
Conforms |
TrustPointe |
|
|
PT-141 |
PT202605 |
VI32 |
2026-06-12 |
Conforms |
Kovera |
|
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
Conforms |
Kovera |
|
|
MOTS-c |
MC202605 |
WF03 |
2026-06-11 |
Conforms |
TrustPointe |
|
|
Semaglutide |
SM202607 |
VI32 |
2026-06-10 |
Conforms |
Kovera |
|
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
|
|
KPV |
KV202606 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
|
|
BPC-157 |
BC202607 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
|
|
Retatrutide |
RT202607 |
WF03 |
2026-06-09 |
Conforms |
Kovera |
|
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-09 |
Conforms |
Kovera |
|
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-09 |
Conforms |
Kovera |
|
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-11 |
Conforms |
TrustPointe |
|
|
Epithalon |
ET202604 |
WF03 |
2026-05-13 |
Conforms |
Kovera |
|
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-13 |
Conforms |
Kovera |
|
|
NAD+ |
NDB202606 |
WF03 |
2026-05-28 |
Conforms |
TrustPointe |
|
|
TB-500 (TB4) |
TB202605 |
WF03 |
2026-05-28 |
Conforms |
TrustPointe |
|
|
Tesamorelin |
TES202605 |
WF03 |
2026-05-28 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RT202605 |
WF03 |
2026-05-27 |
Conforms |
TrustPointe |
|
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-14 |
Conforms |
TrustPointe |
|
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-18 |
Conforms |
TrustPointe |
|
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-18 |
Conforms |
TrustPointe |
|
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-05-07 |
Conforms |
Kovera |
|
|
Tesamorelin |
TES202604 |
WF03 |
2026-04-21 |
Conforms |
Kovera |
|
|
DSIP |
DS202605 |
WF03 |
2026-05-07 |
Conforms |
Kovera |
|
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
Conforms |
Kovera |
|
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
Conforms |
Kovera |
|
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
Conforms |
Kovera |
|
|
Retatrutide |
RT202604 |
WF03 |
2026-04-16 |
Conforms |
TrustPointe |
|
|
MOTS-c |
MC202603 |
VI32 |
2026-04-04 |
Conforms |
Kovera |
|
|
Pinealon |
PN202603 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
|
|
Cagrilintide |
CG202603 |
VI32 |
2026-04-14 |
Conforms |
Kovera |
|
|
Sermorelin |
SER202601 |
VI32 |
2026-04-01 |
Conforms |
Kovera |
|
|
GHK-Cu |
CU202604 |
WF03 |
2026-04-03 |
Conforms |
Kovera |
|
|
SS-31 |
SS202601 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
|
|
Semax |
SX202603 |
WF03 |
2026-03-31 |
Conforms |
Kovera |
|
|
Retatrutide |
RT202603 |
WF03 |
2026-03-30 |
Conforms |
TrustPointe |
|
|
GLOW Blend |
GW202603 |
WF03 |
2026-03-25 |
Conforms |
Kovera |
|
|
Tirzepatide |
TZ202603 |
VI32 |
2026-03-27 |
Conforms |
TrustPointe |
|
|
BPC-157/TB-500 |
BB202604 |
WF03 |
2026-03-26 |
Conforms |
TrustPointe |
|
|
Tesamorelin |
TES202603 |
WF03 |
2026-03-25 |
Conforms |
TrustPointe |
|
|
SS-31 |
SS202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
|
|
CJC-1295 ND/Ipamorelin |
CJIP202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
|
|
KLOW Blend |
KW202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
|
|
BPC-157 |
BC202604 |
WF03 |
2026-03-17 |
Conforms |
Kovera |
|
|
Thymosin Alpha-1 |
TA202601 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
|
|
MOTS-c |
MC202602 |
WF03 |
2026-02-08 |
Conforms |
Kovera |
|
|
NAD+ |
NDB202601 |
VI32 |
2026-02-08 |
Conforms |
Kovera |
|
|
Unbuffered NAD+ |
NDU202601 |
MZ21 |
2026-01-28 |
Conforms |
TrustPointe |
|
|
KPV |
KV202601 |
VI32 |
2026-01-28 |
Conforms |
TrustPointe |
|
|
Ipamorelin |
IP202601 |
WF03 |
2026-01-13 |
Conforms |
TrustPointe |
|
|
TB500 |
TB202601 |
WF03 |
2026-01-13 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RT202602 |
WF03 |
2026-01-13 |
Conforms |
TrustPointe |
|
|
PT-141 |
PT202512 |
VI32 |
2026-01-07 |
Conforms |
BioRegen |
|
|
Semaglutide |
SM202601 |
MZ21 |
2026-01-10 |
Conforms |
TrustPointe |
|
|
Cagrilintide |
CAG202601 |
MZ21 |
2026-01-10 |
Conforms |
TrustPointe |
|
|
Tesamorelin |
TES202601 |
WF03 |
2026-01-06 |
Conforms |
TrustPointe |
|
|
BPC-157 |
BP202512 |
WF03 |
2025-12-30 |
Conforms |
TrustPointe |
|
|
BPC-157/TB-500 |
BB202512 |
WF03 |
2025-12-30 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP260130 |
DF05 |
2025-12-22 |
Conforms |
TrustPointe |
|
|
SS-31 |
SS202512 |
WF03 |
2025-12-19 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP202601 |
DF05 |
2025-12-22 |
Conforms |
TrustPointe |
|
|
Ipamorelin/CJC-1295 (No DAC) |
CJIP202512 |
WF03 |
2025-12-08 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP202511 |
DF05 |
2025-11-10 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP20251020 |
DF05 |
2025-11-10 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP20251001 |
DF05 |
2025-10-13 |
Conforms |
TrustPointe |
|
|
Tirzepatide |
TZ20250915 |
DF05 |
2025-10-03 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP20250929 |
VI32 |
2025-10-03 |
Conforms |
TrustPointe |
|
|
Humanin |
HP20250805 |
WF03 |
2025-09-19 |
Conforms |
BioRegen |
|
|
MOTS-c |
YC20250807 |
WF03 |
2025-09-19 |
Conforms |
BioRegen |
|
|
DSIP |
DS20250820 |
SH07 |
2025-09-19 |
Conforms |
BioRegen |
|
|
SS-31 |
SY20250806 |
WF03 |
2025-09-19 |
Conforms |
BioRegen |
|
|
CJC/Ipamorelin |
CI20250805 |
WF03 |
2025-09-03 |
Conforms |
TrustPointe |
|
|
BPC-157 |
BP20250808 |
WF03 |
2025-09-03 |
Conforms |
TrustPointe |
|
|
Bacteriostatic Water |
BAC20250807 |
SH07 |
2025-08-27 |
Conforms |
BioRegen |
|
|
Tesamorelin |
TS20250722 |
WF03 |
2025-08-20 |
Conforms |
TrustPointe |
|
|
CJC-1295 ND |
CJ20250724 |
WF03 |
2025-08-20 |
Conforms |
TrustPointe |
|
|
Sermorelin |
SM20250723 |
WF03 |
2025-08-20 |
Conforms |
TrustPointe |
|
|
Semaglutide |
SM20250801 |
EJ12 |
2025-08-20 |
Conforms |
TrustPointe |
|
|
Ipamorelin |
IP20250721 |
WF03 |
2025-08-11 |
Conforms |
TrustPointe |
|
|
GHK-Cu |
CU20250717 |
SH07 |
2025-08-08 |
Conforms |
TrustPointe |
|
|
Tirzepatide |
TZ20250730 |
EJ12 |
2025-08-04 |
Conforms |
TrustPointe |
|
|
NAD+ |
ND20250503 |
SH07 |
2025-07-29 |
Conforms |
TrustPointe |
|
|
VIP |
VP20250511 |
SH07 |
2025-07-29 |
Conforms |
TrustPointe |
|
|
Retatrutide |
CD20250708 |
SH07 |
2025-07-24 |
Conforms |
TrustPointe |
|
|
BPC/TB500 |
BB20250630 |
SH07 |
2025-07-17 |
Conforms |
TrustPointe |
|
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-07-17 |
Conforms |
TrustPointe |
Current Heavy Metal Certifications
|
Peptide |
Batch Id |
Manufacturer |
Date |
Class 1 USP |
Full USP |
Laboratory |
|
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-07-01 |
Conforms |
Kovera |
||
|
Retatrutide |
RTT2613 |
WF03 |
2026-07-01 |
Conforms |
Kovera |
||
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
||
|
KPV |
KV202606 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
||
|
BPC-157 |
BC202607 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
||
|
Tesamorelin |
TES202607 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
||
|
Semaglutide |
SM202607 |
VI32 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
Retatrutide |
RT202607 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
MOTS-c |
MC202605 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
PT-141 |
PT202605 |
VI32 |
2026-06-13 |
Conforms |
Kovera |
||
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
Conforms |
Kovera |
||
|
Semaglutide |
SM202607 |
VI32 |
2026-06-11 |
Conforms |
Kovera |
||
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
||
|
KPV |
KV202606 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
||
|
BPC-157 |
BC202607 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
||
|
Retatrutide |
RT202607 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
||
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
||
|
Epithalon |
ET202604 |
WF03 |
2026-05-14 |
Conforms |
Kovera |
||
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-14 |
Conforms |
Kovera |
||
|
NAD+ |
NDB202606 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
||
|
Tesamorelin |
TES202605 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
||
|
Retatrutide |
RT202605 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
||
|
TB-500 |
TB202605 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
||
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-26 |
Conforms |
TrustPointe |
||
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-26 |
Conforms |
TrustPointe |
||
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-26 |
Conforms |
TrustPointe |
||
|
SS-31 |
SS202602 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
||
|
AOD-9604 |
AO202605 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
||
|
GLOW Blend |
GW202603 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
||
|
KLOW Blend |
KW202602 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
||
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-16 |
Conforms |
Kovera |
||
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-16 |
Conforms |
Kovera |
||
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-04-26 |
Conforms |
Kovera |
||
|
Tesamorelin |
TES202604 |
WF03 |
2026-04-22 |
Conforms |
Kovera |
||
|
Pinealon |
PN202603 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
Semax |
SX202603 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
MOTS-c |
MC202602 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
Cagrilintide |
CG202603 |
VI32 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
SS-31 |
SS202601 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
CJC-1295 ND/Ipamorelin |
CJIP202602 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
DSIP |
DS202605 |
WF03 |
2026-04-24 |
Conforms |
Kovera |
||
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
Conforms |
Kovera |
||
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
Conforms |
Kovera |
||
|
Retatrutide |
RT202604 |
WF03 |
2026-04-22 |
Conforms |
Kovera |
||
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
Conforms |
Kovera |
||
|
SS-31 |
SS202601 |
WF03 |
2026-04-02 |
Conforms |
Kovera |
||
|
BPC-157/TB-500 |
BB202604 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
||
|
Cagrilintide |
CG202603 |
VI32 |
2026-03-31 |
Conforms |
Kovera |
||
|
Pinealon |
PN202603 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
GLOW Blend |
GW202603 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
KLOW Blend |
KW202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
CJC-1295 ND/Ipamorelin |
CJIP202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
SS-31 |
SS202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
MOTS-c |
MC202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
Tesamorelin |
TES202603 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
||
|
Sermorelin |
SER202601 |
VI32 |
2026-03-29 |
Conforms |
Kovera |
||
|
MOTS-c |
MC202603 |
VI32 |
2026-04-01 |
Conforms |
Kovera |
||
|
Retatrutide |
RT202603 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
||
|
Semax |
SX202603 |
WF03 |
2026-03-31 |
Conforms |
Kovera |
||
|
GLOW Blend |
GW202603 |
WF03 |
2026-03-26 |
Conforms |
Kovera |
||
|
Tirzepatide |
TZ202603 |
VI32 |
2026-03-26 |
Conforms |
Kovera |
||
|
BPC-157 |
BC202604 |
WF03 |
2026-03-17 |
Conforms |
Kovera |
||
|
Thymosin Alpha-1 |
TA202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
||
|
NAD+ |
NDB202601 |
VI32 |
2026-02-08 |
Conforms |
Kovera |
||
|
Ipamorelin |
IP202601 |
WF03 |
2026-01-26 |
Conforms |
TrustPointe |
||
|
TB500 |
TB202601 |
WF03 |
2026-01-26 |
Conforms |
TrustPointe |
||
|
Retatrutide |
RT202602 |
WF03 |
2026-01-26 |
Conforms |
TrustPointe |
||
|
Semaglutide |
SM202601 |
MZ21 |
2026-01-19 |
Conforms |
TrustPointe |
||
|
Cagrilintide |
CAG202601 |
MZ21 |
2026-01-19 |
Conforms |
TrustPointe |
||
|
Tesamorelin |
TES202601 |
WF03 |
2026-01-19 |
Conforms |
TrustPointe |
||
|
BPC-157 |
BP202512 |
WF03 |
2026-01-08 |
Conforms |
TrustPointe |
||
|
BPC-157/TB-500 |
BB202512 |
WF03 |
2026-01-08 |
Conforms |
TrustPointe |
||
|
Tirzepatide |
TZ20250915 |
DF05 |
2025-12-03 |
Conforms |
TrustPointe |
||
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-11-24 |
Conforms |
TrustPointe |
||
|
BPC-157 |
BP20250808 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
BPC/TB500 |
BB20250630 |
SH07 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
CJC-1295 ND |
CJ20250724 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
GHK-Cu |
CU20250717 |
SH07 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
Ipamorelin |
IP20250721 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
Retatrutide |
RP20251020 |
DF05 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
Sermorelin |
SM20250723 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
SS-31 |
SY20250806 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
Tesamorelin |
TS20250722 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
Tirzepatide |
TZ20250730 |
EJ12 |
2025-11-12 |
Conforms |
TrustPointe |
Current Sterility Certifications
|
Product |
Batch Id |
Manufacturer |
Date |
USP Pass/Fail |
Rapid Pass/Fail |
Laboratory |
File |
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-06-30 |
Pass |
Kovera |
||
|
Retatrutide |
RTT2613 |
WF03 |
2026-06-30 |
Pass |
Kovera |
||
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-26 |
Pass |
TrustPointe |
||
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-26 |
Pass |
TrustPointe |
||
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-26 |
Pass |
TrustPointe |
||
|
MOTS-c |
MC202605 |
WF03 |
2026-06-23 |
Pass |
TrustPointe |
||
|
NAD+ |
NDB202606 |
WF03 |
2026-06-15 |
Pass |
TrustPointe |
||
|
Tesamorelin |
TES202605 |
WF03 |
2026-06-15 |
Pass |
TrustPointe |
||
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
Pass |
Kovera |
||
|
PT-141 |
PT202605 |
VI32 |
2026-06-12 |
Pass |
Kovera |
||
|
Semaglutide |
SM202607 |
VI32 |
2026-06-10 |
Pass |
Kovera |
||
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-10 |
Pass |
Kovera |
||
|
KPV |
KV202606 |
WF03 |
2026-06-10 |
Pass |
Kovera |
||
|
BPC-157 |
BC202607 |
WF03 |
2026-06-10 |
Pass |
Kovera |
||
|
Retatrutide |
RT202605 |
WF03 |
2026-06-12 |
Pass |
Kovera |
||
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-09 |
Pass |
Kovera |
||
|
Retatrutide |
RT202607 |
WF03 |
2026-06-09 |
Pass |
Kovera |
||
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-09 |
Pass |
Kovera |
||
|
Epithalon |
ET202604 |
WF03 |
2026-05-14 |
Pass |
Kovera |
||
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-29 |
Pass |
TrustPointe |
||
|
Epithalon |
ET202604 |
WF03 |
2026-05-14 |
Pass |
Kovera |
||
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-14 |
Pass |
Kovera |
||
|
Reconstitution Solution |
BAC202602 |
VI32 |
2026-05-14 |
Pass |
Kovera |
||
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-14 |
Pass |
Kovera |
||
|
Cagrilintide |
CG202607 |
VI32 |
2026-05-14 |
Pass |
Kovera |
||
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-05-07 |
Pass |
Kovera |
||
|
DSIP |
DS202605 |
WF03 |
2026-05-07 |
Pass |
– |
Kovera |
|
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
Pass |
Kovera |
||
|
Retatrutide |
RT202604 |
WF03 |
2026-04-22 |
Pass |
– |
Kovera |
|
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
– |
Pass |
Kovera |
|
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
– |
Pass |
Kovera |
|
|
Cagrilintide |
CG202603 |
VI32 |
2026-04-12 |
Pass |
– |
Kovera |
|
|
SS-31 |
SS202601 |
WF03 |
2026-04-12 |
– |
Pass |
Kovera |
|
|
MOTS-c |
MC202603 |
VI32 |
2026-04-04 |
Pass |
– |
Kovera |
|
|
Bacteriostatic Water |
BAC202601 |
WF03 |
2026-01-13 |
Pass |
– |
TrustPointe |
|
|
Bacteriostatic Water |
BAC20250807 |
SH07 |
2025-09-09 |
Pass |
– |
TrustPointe |
|
|
Meta-Z |
MZR20250713 |
DF05 |
2025-08-26 |
Pass |
– |
TrustPointe |
Verifiable certificates
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
Beware of fraudulent laboratories
Not only must one remain vigilant about potentially fraudulent certificates, one must also be aware that there are third-party laboratories whose results cannot be considered reliable or scientifically valid. Unfortunately, there is significant evidence to suggest that one of the most popular third-party testing labs does not use scientifically sound methodologies and, in some cases, has fabricated results. There isn’t an easy remedy for this problem, but when labs are particularly bad, there tend to be a lot of discussion threads on various social platforms.
Interpreting Endotoxin Results (via TrustPointe)
Our friends at TrustPointe have provided the following detailed explanation to help interpret the results of the endotoxin testing.
We use the Charles River Endosafe PTS system to test for bacterial endotoxins following USP <85> guidelines:
- USP <85> Bacterial Endotoxin Result: <x.xx EU/mL
Because it’s reported as “<x.xx” this indicates the test did not detect endotoxin above the detection limit of the cartridge. - If a result is above the limit of detection of the cartridge, it will be reported as a number (without the “<“).
The following are suitability parameters that verify the system was working properly and the sample prep dilution is appropriate for accurate results. Peptides often interfere with endotoxin detection due to their tendency to bind or mask endotoxins, which can lead to inaccurate low results. To overcome this, samples are typically tested at a large dilution to reduce matrix interference and ensure reliable recovery and detection in compliance with USP <85>. If the dilution is not correct, the run will fail suitability and we’ll need to adjust the dilution to ensure accurate results. We provide the suitability data to customers for transparency and so they can be confident in the results.
USP <85> Sample CV %:
- CV stands for coefficient of variation, a measure of repeatability.
- For our lab, CV has to be <25% or the result to be considered valid
USP <85> Spike CV %:
- This refers to the precision of the positive control (spiked sample).
- Again, for our lab CV has to be <25% or the result to be considered valid
USP <85> Spike Recovery
- This tells us how much of the known endotoxin spike was recovered from your sample.
- The acceptable range is 50–200% per USP <85>
Related Products
Browse more in Metabolics.
Related products
